{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:32:22Z","timestamp":1773675142872,"version":"3.50.1"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,29]],"date-time":"2015-07-29T00:00:00Z","timestamp":1438128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Microbiology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.mib.2015.07.006","type":"journal-article","created":{"date-parts":[[2015,9,5]],"date-time":"2015-09-05T03:46:01Z","timestamp":1441424761000},"page":"96-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Anti-infective vaccination in the 21st century\u2014new horizons for personal and public health"],"prefix":"10.1016","volume":"27","author":[{"given":"Ingrid L","family":"Scully","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kena","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin U","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6413-1718","authenticated-orcid":false,"given":"Annaliesa S","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mib.2015.07.006_bib0450","first-page":"913","article-title":"Vaccination coverage among children in kindergarten\u2014United States, 2013\u201314 school year","volume":"63","author":"Seither","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.mib.2015.07.006_bib0455","series-title":"Transcript for CDC Telebriefing: Measles in the United States, 2015","author":"Prevention CfDCa","year":"2015"},{"key":"10.1016\/j.mib.2015.07.006_bib0460","first-page":"373","article-title":"Measles\u2014United States, January 4\u2013April 2, 2015","volume":"64","author":"Clemmons","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.mib.2015.07.006_bib0465","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0264-410X(98)00385-5","article-title":"A new method of non-cross-linking conjugation of polysaccharides to proteins via thioether bonds for the preparation of saccharide\u2013protein conjugate vaccines","volume":"17","author":"Pawlowski","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.mib.2015.07.006_bib0470","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/cid\/cir735","article-title":"Current epidemiology and trends in invasive Haemophilus influenzae disease\u2014United States, 1989\u20132008","volume":"53","author":"MacNeil","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2015.07.006_bib0475","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.mib.2015.07.006_bib0480","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/01.inf.0000129685.04847.94","article-title":"Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente","volume":"23","author":"Black","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.mib.2015.07.006_bib0485","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.294.16.2043","article-title":"Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine","volume":"294","author":"Lexau","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.mib.2015.07.006_bib0490","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1086\/503805","article-title":"Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease","volume":"193","author":"Hammitt","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.mib.2015.07.006_bib0495","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1473-3099(11)70090-1","article-title":"Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study","volume":"11","author":"Miller","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.mib.2015.07.006_bib0500","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1586\/erv.10.145","article-title":"Global prevailing and emerging pediatric pneumococcal serotypes","volume":"10","author":"McIntosh","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.mib.2015.07.006_bib0505","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.vaccine.2014.02.002","article-title":"Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60\u201364 years of age","volume":"32","author":"Greenberg","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.mib.2015.07.006_bib0510","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1016\/j.vaccine.2013.05.010","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.mib.2015.07.006_bib0515","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1016\/j.vaccine.2013.04.084","article-title":"Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.mib.2015.07.006_bib0520","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mib.2015.07.006_bib0525","doi-asserted-by":"crossref","first-page":"8870","DOI":"10.1016\/j.vaccine.2011.09.078","article-title":"Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model","volume":"29","author":"Skinner","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.mib.2015.07.006_bib0530","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1358\/dot.2011.47.3.1556471","article-title":"New conjugate vaccines for the prevention of pneumococcal disease in developing countries","volume":"47","author":"Ginsburg","year":"2011","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.mib.2015.07.006_bib0535","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1128\/MMBR.00056-12","article-title":"Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease","volume":"77","author":"McNeil","year":"2013","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.mib.2015.07.006_bib0540","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/erv.09.48","article-title":"Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs","volume":"8","author":"Trotter","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.mib.2015.07.006_bib0545","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":"Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity","volume":"17","author":"Campbell","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.mib.2015.07.006_bib0550","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1574-6976.2006.00053.x","article-title":"Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines","volume":"31","author":"Trotter","year":"2007","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.mib.2015.07.006_bib0555","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.mib.2015.07.006_bib0560","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1046\/j.1365-2958.2000.02000.x","article-title":"Repeat-associated phase variable genes in the complete genome sequence of Neisseria meningitidis strain MC58","volume":"37","author":"Saunders","year":"2000","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.mib.2015.07.006_bib0565","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1016\/j.vaccine.2011.04.092","article-title":"Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States","volume":"29","author":"Wang","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.mib.2015.07.006_bib0570","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1016\/j.vaccine.2009.01.075","article-title":"Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide","volume":"27","author":"McNeil","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.mib.2015.07.006_bib0575","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/600141","article-title":"Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis","volume":"200","author":"Murphy","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.mib.2015.07.006_bib0580","doi-asserted-by":"crossref","first-page":"5959","DOI":"10.1093\/nar\/gkp634","article-title":"Detecting species-site dependencies in large multiple sequence alignments","volume":"37","author":"Schwarz","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.mib.2015.07.006_bib0585","first-page":"7","article-title":"Trumenba: a serogroup B meningococcal vaccine","volume":"57","year":"2015","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.mib.2015.07.006_bib0590","first-page":"97","article-title":"In brief: prevention of meningococcus B disease","volume":"55","year":"2013","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.mib.2015.07.006_bib0595","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/INF.0b013e31829aa63b","article-title":"A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups","volume":"32","author":"Hoiseth","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.mib.2015.07.006_bib0600","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1128\/JCM.38.9.3323-3328.2000","article-title":"Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team","volume":"38","author":"Tondella","year":"2000","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.mib.2015.07.006_bib0605","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1128\/IAI.72.7.4217-4223.2004","article-title":"NadA diversity and carriage in Neisseria meningitidis","volume":"72","author":"Comanducci","year":"2004","journal-title":"Infect Immun"},{"issue":"Suppl 2","key":"10.1016\/j.mib.2015.07.006_bib0610","doi-asserted-by":"crossref","first-page":"B13","DOI":"10.1016\/j.vaccine.2009.04.062","article-title":"Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution","volume":"27","author":"Marc LaForce","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.mib.2015.07.006_bib0615","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(13)61612-8","article-title":"Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]","volume":"383","author":"Daugla","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.mib.2015.07.006_bib0620","first-page":"57","article-title":"Meningococcal A conjugate vaccine: updated guidance, February 2015","volume":"90","year":"2015","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.mib.2015.07.006_bib0625","series-title":"Highlights of Prescribing Information","author":"Merck","year":"2015"},{"key":"10.1016\/j.mib.2015.07.006_bib0630","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI28607","article-title":"Prophylactic human papillomavirus vaccines","volume":"116","author":"Lowy","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.mib.2015.07.006_bib0635","first-page":"620","article-title":"Human papillomavirus vaccination coverage among adolescents, 2007\u20132013, and postlicensure vaccine safety monitoring, 2006\u20132014\u2014United States","volume":"63","author":"Stokley","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.mib.2015.07.006_bib0640","first-page":"626","article-title":"FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Centers for Disease C and Prevention","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.mib.2015.07.006_bib0645","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1016\/S1470-2045(14)71191-X","article-title":"FDA approves new upgraded Gardasil 9","volume":"16","author":"Kirby","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.mib.2015.07.006_bib0650","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1016\/j.vaccine.2013.05.037","article-title":"Rotavirus vaccines WHO position paper: January 2013\u2014recommendations","volume":"31","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.mib.2015.07.006_bib0655","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa052434","article-title":"Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis","volume":"354","author":"Ruiz-Palacios","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mib.2015.07.006_bib0660","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(07)61744-9","article-title":"Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study","volume":"370","author":"Vesikari","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.mib.2015.07.006_bib0665","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa052664","article-title":"Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine","volume":"354","author":"Vesikari","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mib.2015.07.006_bib0670","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.cmi.2015.01.027","article-title":"Rotavirus vaccines: a story of success","volume":"21","author":"Kollaritsch","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.mib.2015.07.006_bib0675","first-page":"1007","article-title":"Withdrawal of rotavirus vaccine recommendation","volume":"48","year":"1999","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Suppl 1","key":"10.1016\/j.mib.2015.07.006_bib0680","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jinf.2013.09.010","article-title":"Rotavirus vaccines: successes and challenges","volume":"68","author":"Glass","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.mib.2015.07.006_bib0685","series-title":"Vaccines","first-page":"1","article-title":"A short history of vaccination","author":"Plotkin","year":"2004"},{"issue":"Suppl","key":"10.1016\/j.mib.2015.07.006_bib0690","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/nrmicro2460","article-title":"Dengue: a continuing global threat","volume":"8","author":"Guzman","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.mib.2015.07.006_bib0695","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.mib.2015.07.006_bib0700","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mib.2015.07.006_bib0705","series-title":"Statement on the 1st Meeting of the IHR Emergency Committee on the 2014 Ebola Outbreak in West Africa","author":"WHO","year":"2014"},{"key":"10.1016\/j.mib.2015.07.006_bib0710","series-title":"Ebola Virus Disease","author":"WHO","year":"2015"},{"key":"10.1016\/j.mib.2015.07.006_bib0715","series-title":"Ebola Situation Report\u201422 April 2015","author":"WHO","year":"2015"},{"key":"10.1016\/j.mib.2015.07.006_bib0720","series-title":"Recommendations for Accelerating the Development of Ebola Vaccines","first-page":"1","author":"CIDRAP","year":"2015"},{"key":"10.1016\/j.mib.2015.07.006_bib0725","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1410863","article-title":"Chimpanzee adenovirus vector Ebola vaccine\u2014preliminary report","author":"Ledgerwood","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mib.2015.07.006_bib0730","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fimmu.2014.00109","article-title":"Covering all the bases: preclinical development of an effective Staphylococcus aureus vaccine","volume":"5","author":"Scully","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.mib.2015.07.006_bib0735","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.vaccine.2015.02.024","article-title":"A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults","volume":"33","author":"Nissen","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.mib.2015.07.006_bib0740","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1080\/21645515.2015.1011021","article-title":"Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: results of a randomized phase I trial","volume":"11","author":"Levy","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.mib.2015.07.006_bib0745","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1073\/pnas.1424924112","article-title":"Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus","volume":"112","author":"Bagnoli","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.mib.2015.07.006_bib0750","first-page":"i","article-title":"US FDA grants fast-track designation to Sanofi Pasteur's investigational Clostridium difficile vaccine","volume":"52","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"Pt 7","key":"10.1016\/j.mib.2015.07.006_bib0755","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1099\/mic.0.066712-0","article-title":"A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile","volume":"159","author":"Donald","year":"2013","journal-title":"Microbiology"},{"key":"10.1016\/j.mib.2015.07.006_bib0760","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4161\/hv.35858","article-title":"Adult vaccination","volume":"11","author":"Swanson","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.mib.2015.07.006_bib0765","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJMoa0907635","article-title":"Treatment with monoclonal antibodies against Clostridium difficile toxins","volume":"362","author":"Lowy","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mib.2015.07.006_bib0770","series-title":"Guiding Principles for Development of ACIP Recommendations for Vaccination During Pregnancy and Breastfeeding","author":"Practices ACoI","year":"2008"},{"key":"10.1016\/j.mib.2015.07.006_bib0775","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJMoa1401480","article-title":"Influenza vaccination of pregnant women and protection of their infants","volume":"371","author":"Madhi","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mib.2015.07.006_bib0780","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1056\/NEJMoa0708630","article-title":"Effectiveness of maternal influenza immunization in mothers and infants","volume":"359","author":"Zaman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mib.2015.07.006_bib0785","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/AOG.0000000000000581","article-title":"Vaccinations for pregnant women","volume":"125","author":"Swamy","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.mib.2015.07.006_bib0790","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-065X.2010.00972.x","article-title":"Biological challenges and technological opportunities for respiratory syncytial virus vaccine development","volume":"239","author":"Graham","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.mib.2015.07.006_bib0795","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1542\/peds.2014-1666","article-title":"Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection","volume":"134","author":"American Academy of Pediatrics Committee on Infectious D and C American Academy of Pediatrics Bronchiolitis Guidelines","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.mib.2015.07.006_bib0800","first-page":"83","article-title":"Structure and function of respiratory syncytial virus surface glycoproteins","volume":"372","author":"McLellan","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.mib.2015.07.006_bib0805","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.mib.2015.07.006_bib0810","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.mib.2015.07.006_bib0815","series-title":"Global Update on the Health Sector Response to HIV, 2014","first-page":"1","author":"WHO","year":"2014"},{"key":"10.1016\/j.mib.2015.07.006_bib0820","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0140-6736(03)13802-0","article-title":"Decline in the AIDS and death rates in the EuroSIDA study: an observational study","volume":"362","author":"Mocroft","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.mib.2015.07.006_bib0825","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mib.2015.07.006_bib0830","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12985-014-0221-0","article-title":"HIV-1 vaccine immunogen design strategies","volume":"12","author":"Mann","year":"2015","journal-title":"Virol J"},{"key":"10.1016\/j.mib.2015.07.006_bib0835","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/387183a0","article-title":"Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection","volume":"387","author":"Chun","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.mib.2015.07.006_bib0840","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.3390\/v6103968","article-title":"Challenges in the design of a T cell vaccine in the context of HIV-1 diversity","volume":"6","author":"Tongo","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.mib.2015.07.006_bib0845","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/imr.12069","article-title":"CD8(+) T-cell effector function and transcriptional regulation during HIV pathogenesis","volume":"254","author":"Demers","year":"2013","journal-title":"Immunol Rev"},{"key":"10.1016\/j.mib.2015.07.006_bib0850","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mib.2015.07.006_bib0855","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrd4364","article-title":"The HIV pipeline","volume":"13","author":"Wong","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.mib.2015.07.006_bib0860","series-title":"Global Prevalence and Incidence of Selected Curable Sexually Transmitted Infections\u20142008","author":"WHO","year":"2012"},{"key":"10.1016\/j.mib.2015.07.006_bib0865","series-title":"Sexually Transmitted Disease Surveillance 2012","author":"CDC","year":"2013"},{"key":"10.1016\/j.mib.2015.07.006_bib0870","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/s-0033-1361822","article-title":"Microbiota and pelvic inflammatory disease","volume":"32","author":"Sharma","year":"2014","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.mib.2015.07.006_bib0875","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.vaccine.2013.10.016","article-title":"Towards a safe and effective chlamydial vaccine: lessons from the eye","volume":"32","author":"Mabey","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.mib.2015.07.006_bib0880","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.vaccine.2013.08.020","article-title":"Development status and future prospects for a vaccine against Chlamydia trachomatis infection","volume":"32","author":"Hafner","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.mib.2015.07.006_bib0885","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.1128\/IAI.69.10.6240-6247.2001","article-title":"Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge","volume":"69","author":"Pal","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.mib.2015.07.006_bib0890","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1084\/jem.20111266","article-title":"A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates","volume":"208","author":"Kari","year":"2011","journal-title":"J Exp Med"}],"container-title":["Current Opinion in Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1369527415000971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1369527415000971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T01:25:04Z","timestamp":1599528304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1369527415000971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":89,"alternative-id":["S1369527415000971"],"URL":"https:\/\/doi.org\/10.1016\/j.mib.2015.07.006","relation":{},"ISSN":["1369-5274"],"issn-type":[{"value":"1369-5274","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-infective vaccination in the 21st century\u2014new horizons for personal and public health","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mib.2015.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}